Render Target: STATIC
Render Timestamp: 2025-01-21T12:50:32.774Z
Commit: da7e4f2f0d1aed1f1f8e20e4e2ecab8f33cbd595
XML generation date: 2024-09-30 01:59:39.707
Product last modified at: 2025-01-15T20:30:09.836Z
Cell Signaling Technology Logo

Basket Updated

0

Items added

1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

ANGPTL3 (F8N1Q) Rabbit mAb #26533

Filter:
  • WB
Western Blotting Image 1: ANGPTL3 (F8N1Q) Rabbit mAb
Western blot analysis of whole cell extracts (lane 1) and concentrated, serum-free culture medium (lane 2) from HuH-7 cells, using ANGPTL3 (F8N1Q) Rabbit mAb (upper) or GAPDH (D16H11) XP® Rabbit mAb #5174 (lower).

To Purchase # 26533

Cat. # Size Qty. Price Ships
26533T 20 µl
$168
26533S 100 µl
$371

Supporting Data

REACTIVITY H
SENSITIVITY Endogenous
MW (kDa) 30-38, 55-65
Source/Isotype Rabbit IgG
Application Key:
  • WB-Western Blotting 
Species Cross-Reactivity Key:
  • H-Human 
  • Related Products

Product Information

Product Usage Information

Application Dilution
Western Blotting 1:1000
Simple Western™ 1:10 - 1:50

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

Protocol

Specificity / Sensitivity

ANGPTL3 (FN1Q) Rabbit mAb recognizes endogenous levels of total ANGPTL3 protein. This antibody recognizes both the full-length protein (UniProt #Q9Y5C1) and the cleaved C-terminal fibrinogen-like domain (ANGPTL3-FLD).

Species Reactivity:

Human

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human ANGPTL3 protein.

Background

Angiopoietin-like 3 (ANGPTL3) is a secreted protein primarily expressed in liver and a regulator of fatty acid homeostasis (1). The angiopoietin-like family contains a signal peptide, an N-terminal coiled-coil domain (CCD), a linker peptide, and a C-terminal fibrinogen-like domain (FLD). Cleavage of the CCD and FLD occurs within the linker peptide, and is required for the activity of both domains (2). ANGPTL3-CCD, in concert with ANGPTL4/ANGPTL8, increases circulating triglyceride levels by inhibiting lipoprotein lipase, a hydrolase of LDL cholesterol (2,3). ANGPTL3-CCD also directly inhibits endothelial lipase, the enzyme responsible for HDL cholesterol hydrolysis (8,9). Thus, ANGPTL3-deficient mice have low levels of plasma HDL cholesterol, a risk factor for atherosclerosis (8,9). Unlike traditional angiopoietins, ANGPTL3-FLD does not bind the Tie2 receptor (4). ANGPTL3-FLD has been demonstrated to stimulate angiogenesis in endothelial cells via binding to integrin αVβ3, and to facilitate lipolysis in adipocytes via stimulation of the PDGFRβ-BRAF-ERK pathway (4,5). ANGPTL3 is currently a therapeutic target in patients with high-LDL dyslipidaemia, and can be inhibited with the use of monoclonal antibodies or antisense nucleotides (6,7).
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit our Trademark Information page.